Safety of botulinum toxin type A: A systematic review and meta-analysis

Current Medical Research and Opinion

Volumn 20, Issue 7, 2004, Pages 981-990

  Naumann, Markus ^a   Jankovic, Joseph ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse events; Botulinum toxin type A; Randomized controlled trials; Safety; Systematic review; Tolerability

Indexed keywords

BOTULINUM TOXIN A;

BACKACHE; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE SEVERITY; DRUG EFFECT; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSTONIA; EMBASE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERHIDROSIS; INJECTION PAIN; INJECTION SITE; INJECTION SITE REACTION; MEDLINE; META ANALYSIS; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NECK PAIN; OUTCOMES RESEARCH; PAIN; PTOSIS; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SORENESS; SPASTICITY; SYSTEMATIC REVIEW; URINARY TRACT DISEASE;

BOTULINUM TOXIN TYPE A; HUMANS; INJECTIONS, INTRAMUSCULAR; NEUROMUSCULAR AGENTS; RANDOMIZED CONTROLLED TRIALS; SAFETY;

EID: 3242670022     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003962     Document Type: Review

References (60)

1. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. New Engl J Med 1991;324(17):1186-94
2. Berardelli A, Abbruzzese G, Bertolasi L, et al. Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology. Ital J Neurol Sci 1997;18(5):261-9
3. Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Invest Drugs 2001;10(8):1531-44
4. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001;248(Suppl 1):3-10
5. Brin M. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997;6:S146-8
6. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1143-53
7. The Cochrane Collaboration. Review Manager (Revman) version 4.1 (Software)
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
9. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46(5):1306-10
10. FDA Center for Biologics Evaulation and Research. Botulinum toxin A for temporary reduction of glabellar lines: results of a double-blind, placebo-controlled study [Protocol 023]. Statistical review available online at http://www.fda.gov/cber/review/botua11041202r3.pdf. Accessed December 2002
11. Marras CAD, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001;56(5):605-10
12. Boyd RN, Dobson F, Parrott J, et al. The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. Eur J Neurol 2001;8(Suppl 5):109-19
13. Love SC, Valentine JP, Blair EM, Price CJ, Cole JH, Chauvel PJ. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial. Eur J Neurol 2001;8(Suppl 5):50-8
14. Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001;56(11):1523-8
15. Annese V, Basciani M, Perri F, et al. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology 1996;111(6):1418-24
16. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. Br Med J 2001;323(7313):596-9
17. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002;46(6):840-9
18. Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 2002;28(9):822-7
19. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. New Engl J Med 2002;347(6):395-400
20. de Seze M, Petit H, Gallien P, et al. Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 2002;42(1):56-62
21. Odderson IR. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis. Dermatol Surg 2002;28(6):480-3
22. Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder JM. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001;41(7):658-64
23. Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000;137(3):331-7
24. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40(6):445-50
25. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache 2000;40(3):231-6
26. Koman LA, Mooney JF, 3rd, Smith BP, Walker F, Leon JM. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000;20(1):108-15
27. Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 1999;35(1):71-7
28. Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio AR, Albanese A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. New Engl J Med 1998;338(4):217-20
29. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996;11(3):250-6
30. Henderson JM, Ghika JA, Van Melle G, Haller E, Einstein R. Botulinum toxin A in non-dystonic tremors. Eur Neurol 1996;36(1):29-35
31. Pahwa R, Busenbark K, Swanson-Hyland EF, et al. Botulinum toxin treatment of essential head tremor. Neurology 1995;45(4):822-4
32. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995;45(4):712-7
33. Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer's cramp: a double-blind study. Neurology 1993;43(1):183-5
34. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology 1992;42(3 Pt 1):627-30
35. Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991;101(6 Pt 1):630-4
36. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 2001;56(10):1290-3
37. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998;23(15):1662-6
38. Fiorini A, Corti RE, Valero JL, Bai JC, Boerr L. Botulinum toxin is effective in the short-term treatment of esophageal achalasia. Preliminary results of a randomized trial. Acta Gastro-Enterol Latinoam 1996;26(3):155-7
39. Colak T, Ipek T, Kanik A, Aydin S. A randomized trial of botulinum toxin vs lidocain pomade for chronic anal fissure. Acta Gastro-Enterol Belg 2002;65(4):187-90
40. Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol 2002;47(6):834-40
41. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 1999;10(1):1-9
42. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2(8501):245-7
43. Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN. Intrasphincteric botulinum toxin for the treatment of achalasia. New Engl J Med. 1995;332(12):774-8
44. Brisinda G, Maria G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. New Engl J Med. 1999;341(2):65-9
45. Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol 1996;41(1):51-65
46. Taylor JD, Kraft SP, Kazdan MS, Flanders M, Cadera W, Orton RB. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol 1991;26(3):133-8
47. Kalra HK, Magoon EH. Side effects of the use of botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm. Ophthalmic Surg 1990;21(5):335-8
48. Aramideh M, Ongerboer de Visser BW, Brans JW, Koelman JH, Speelman JD. Pretarsal application of botulinum toxin for treatment of blepharospasm. J Neurol Neurosurg Psychiatry 1995;59(3):309-11
49. Cakmur R, Ozturk V, Uzunel F, Donmez B, Idiman F. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 2002;249(1):64-8
50. More on NSAIDs [online]. Bandolier Journal. 1998;52. Available from http://www.jr2.ox.ac.uk/bandolier/band53/b53-4.html. Accessed September 2003
51. NSAID-induced GI injury [online]. Bandolier Journal. 1997;39. Available from http://www.jr2.ox.ac.uk/bandolier/band39/b39.html. Accessed September 2003
52. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain 2001;17(4):284-95
53. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999;159(16):1931-7
54. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of post herpetic neuralgia: a randomized controlled trial. J Am Med Assoc 1998;280(21):1837-42
55. Naumann M, Moore AP. Long-term safety of botulinum toxin type A. Mov Disord 2003;18(9):1080-1
56. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17(6):1288-93
57. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003;60(7):1186-8
58. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999;53(9):2102-7
59. Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002;59(3):418-20
60. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997;6:S146-68